Forbion Capital Partners Investor

Forbion Capital Partners is a Netherlands-based venture capital firm focused on investing in life sciences companies in drug development as well as MedTech companies addressing high medical needs. Forbion's investment team of nine investment professionals has built an impressive performance track record since the late nineties with successful investments in Rhein Biotech, Crucell, Neutec, Glycart, Borean, Impella, Alantos, Acorda, Fovea and PanGenetics. Current assets under management exceed $500M, split between three active funds. Finally, Forbion co-manages BioGeneration Ventures, an early stage fund focused on academic spin-outs and seed investments in the Netherlands.
Technology: N/A
Industry: Preventive/Precision Medicine
Headquarters: Naarden, Noord-Holland, The Netherlands
Founded Date: 2006
Employees Number: 11-50
Funding Status: N/A
Investor Type: Venture Capital
Investment Stage: Early Stage Venture, Late Stage Venture
Number Of Exits: 31

Visit Website
Register and Claim Ownership